Premium
Benzyl isothiocyanate targets chemoresistant and metastatic head and neck squamous carcinoma cells
Author(s) -
Wolf M. Allison,
Palumbo Allison,
Hardman W. Elaine,
Claudio Pier Paolo
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.822.22
Subject(s) - benzyl isothiocyanate , head and neck squamous cell carcinoma , cisplatin , medicine , cancer research , oncology , head and neck cancer , cell culture , cancer , isothiocyanate , chemotherapy , chemistry , biology , genetics , biochemistry
Approximately 500,000 cases of head and neck squamous cell carcinoma (HNSCC) are reported worldwide each year. Despite recent improvements in cancer treatment, the increase in overall survival of advanced HNSCC has not improved in the past 3 decades. Poor outcome of advanced HNSCC is mainly attributed to chemoresistance and metastasis. Consequently, the need for new therapeutic options to enhance survival of patients with advanced HNSCC is needed. Benzyl isothiocyanate (BITC), a natural compound found in cruciferous vegetables, is showing promising results in targeting chemoresistant and metastatic HNSCC cell lines. Our data suggests that BITC decreased the viability of two HNSCC cell lines (HN30 and HN12) greater when combined with cisplatin, than with treatment of BITC or cisplatin alone after 24, 48 and 72 hrs. A migration assay indicated that the HN12 and HN30 cell line are inhibited by BITC in a dose dependent manner. Additionally, the same wound‐healing assay also showed that 10μM BITC inhibited migration of the highly metastatic HN12 cell line, and when combined with 10μM cisplatin this effect appeared to be enhanced. Treatment with cisplatin alone resulted in migration rates that are similar to the vehicle control. These data altogether suggest that BITC is a novel treatment option for chemoresistant HNSCC.